Cargando…
Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8(+) T cells for adoptive immunotherapy
Adoptive T cell therapy has shown clinical potential for patients with cancer, though effective treatment is dependent on longevity and potency of the exploited tumor-reactive T cells. Previously, we showed that ex vivo inhibition of AKT using the research compound Akt-inhibitor VIII retained differ...
Autores principales: | Mousset, Charlotte M., Hobo, Willemijn, Ji, Yun, Fredrix, Hanny, De Giorgi, Valeria, Allison, Robert D., Kester, Michel G. D., Falkenburg, J. H. Frederik, Schaap, Nicolaas P. M., Jansen, Joop H., Gattinoni, Luca, Dolstra, Harry, van der Waart, Anniek B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169586/ https://www.ncbi.nlm.nih.gov/pubmed/30288356 http://dx.doi.org/10.1080/2162402X.2018.1488565 |
Ejemplares similares
-
siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice
por: van der Waart, Anniek B., et al.
Publicado: (2015) -
Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo
por: Thordardottir, Soley, et al.
Publicado: (2017) -
Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8(+) T cells
por: Mousset, Charlotte M., et al.
Publicado: (2020) -
Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)
por: Hoogstad-van Evert, Janneke, et al.
Publicado: (2019) -
Clinically applicable CD34(+)-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses
por: van Eck van der Sluijs, Jesper, et al.
Publicado: (2021)